| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576154 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10369117 | BAUSCH AND LOMB INC | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10058615 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US11357738 | BAUSCH AND LOMB INC | Semifluorinated compounds and their compositions |
Sep, 2036
(12 years from now) | |
| US10507132 | BAUSCH AND LOMB INC | Topical administration method |
Jun, 2037
(13 years from now) | |
Miebo is owned by Bausch And Lomb Inc.
Miebo contains Perfluorohexyloctane.
Miebo has a total of 6 drug patents out of which 0 drug patents have expired.
Miebo was authorised for market use on 18 May, 2023.
Miebo is available in solution/drops;ophthalmic dosage forms.
Miebo can be used as treatment of the signs and symptoms of dry eye disease (ded).
Drug patent challenges can be filed against Miebo from 19 May, 2027.
The generics of Miebo are possible to be released after 21 June, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
MIEBO family patents
